This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bet on These 5 High Earnings Yield Stocks to Book Profits
by Zacks Equity Research
Check out these five high earnings yield stocks for a powerful portfolio.
Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 14.21% and 2.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
WIll Allergan (AGN) Beat Estimates This Earnings Season?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.
Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.
Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Guardant Health (GH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.
Zacks.com featured highlights include: Koppers, Alaska Air, Guess?, Lionsgate and Jazz Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Koppers, Alaska Air, Guess?, Lionsgate and Jazz Pharmaceuticals
Invest in These 5 High Earnings Yield Stocks Right Away
by Zacks Equity Research
Here are five stocks with high earnings yield that can be picked for a solid portfolio.
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.
Why the Earnings Surprise Streak Could Continue for Jazz (JAZZ)
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
by Zacks Equity Research
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
5 High Earnings Yield Stocks to Buy for a Rewarding Portfolio
by Zacks Equity Research
Here are five stocks with high earnings yield that can be picked for a solid portfolio.
Jazz Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?